Molecular Cancer Diagnostics Market

Table of Contents

One: Executive Summary
Introduction
Market for Molecular Cancer Diagnostics

• • Table 1-1: Global Molecular Cancer Diagnostics Market, 2019-2025 ($ millions)

Scope and Methodology

Two: Industry Overview
Introduction
Global Cancer Burden

• • Figure 2-1: Global Cancer Incidence Trends 2010-2040
• • Figure 2-2: Incidence of Cancer by Type, 2018 (Lung, Breast, Colorectum, Prostate, Stomach, Liver, Oesophagus, Cervix uteri, Thyroid, Bladder)
• • Figure 2-3: Distribution of Cancer Incidence by Type, 2018 (%) (Lung, Breast, Colorectum, Prostate, Stomach, Liver, Oesophagus, Cervix uteri, Thyroid, Bladder, Others)

Market Trends in Molecular Diagnostics

• Next Generation Sequencing or Massively Parallel Sequencing in Cancer Diagnostics
  • Figure 2-4: Distribution of Sequencing Diagnostic Trials, as of February 2020 (%) (Lung/Bronchial, Gastrointestinal/Digestive, Leukemia, Breast, Others)
• Role of Molecular Diagnostics in Hereditary Cancer Diagnosis
  • Table 2-1: Select Innovations in Molecular Cancer Risk Detection and Prevention
• Predictive Biomarker Tests for Identifying Drug-Gene Match
• Liquid Biopsy-based Non-Invasive Cancer Molecular Diagnostics
  • Table 2-2: Companies Offering Liquid Biopsy-based Molecular Cancer Assays
• Molecular Diagnosis of Cancers of Unknown Primary Site (CUP)
• Artificial Intelligence

Evolution of Molecular Cancer Diagnostics and Current Status

• • Table 2-3: Selected Molecular Companion and Complementary Assays for Cancer
• Clinical Utility of Molecular Diagnostics
• Laboratory Developed Tests (LDT)
  • Figure 2-5: Molecular Cancer Diagnostics, LTD Market Distribution, 2019 (%)

Three: Global Cancer Molecular Diagnostics Market
Introduction

• • Table 3-1: Global Molecular Cancer Diagnostics Markets, By Region (2019-2025) ($, Million) (North America, Europe, APAC, RoW, Total)
• • Table 3-2: Global Molecular Cancer Diagnostics Markets, By Segment (2019-2025) ($, Million) (Molecular Histology; Molecular Assays, including CDx; Total. Molecular HPV)
• • Table 3-3: Global Molecular Cancer Diagnostics Markets, Estimated Distribution of Sales by Technology/Method (2020-2025) (%) (PCR, ISH, Arrays, NGS, Others)

Competitor Analysis

• • Table 3-4: Estimated Molecular Cancer Test Revenues of Selected IVD Vendors, 2019 ($ millions)
• • Figure 3-1: Estimated Molecular Cancer Test Market Value Distribution, 2019 (%)

Relevant DNA/RNA Variants

• • Table 3-5: Human Genome and Cancer Gene Identification
• • Table 3-6: Global Molecular Cancer Diagnostics Markets by Select Cancer Target (Breast/Ovarian, Colorectal, Leukemia/Lymphoma, Lung, Melanoma), 2019-2025 ($ millions)
• • Table 3-7: Cancer Incidence by Type, 2018 data
• • Table 3-8: Relevant DNA/RNA Variants for Top Six Cancer Types
• • Table 3-9: Relevant DNA/RNA Variants for High Incidence Cancer Types (excluding top six)

Four: Cancer Molecular Diagnostics Markets, North America
Introduction

• • Table 4-1: North America Molecular Dx Market for Oncology – Histology, Assays, 2019-2025 ($ millions) (Molecular Histology; Molecular Assays, including CDx; Total. Molecular HPV)
• • Table 4-2: North America (United States, Canada) Molecular Dx Market for Oncology, 2020-2025 ($ millions)

The Burden of Cancer in North America

• • Table 4-3: United States – Top 10 Cancer Incidences, 2018
• • Figure 4-1: United States – Leading Cancer Incidence Distribution, 2018 (%) (Breast, Lung, Prostate, Colorectum, Bladder, Non-Hodgkin lymphoma, Melanoma of skin, Thyroid, Kidney, Corpus uteri, Others)
• • Table 4-4: Canada – Top 10 Cancer Incidences, 2018
• • Figure 4-2: Canada – Leading Cancer Incidence Distribution, 2018 (%) (Breast, Lung, Prostate, Colorectum, Bladder, Non-Hodgkin lymphoma, Melanoma of skin, Thyroid, Kidney, Corpus uteri, Others)

Reimbursement Structure, Challenges and Recent Activity

• U.S. Reimbursement Structure
  • Table 4-5: Medicare Reimbursement Amounts for Molecular Diagnostics Oncology, 2018-2020
  • Figure 4-3: Average Medicare Reimbursement for Molecular Dx Oncology, 2018-2020 ($)
• Canada Reimbursement Structure

Five: Cancer Molecular Diagnostics Markets, Europe
Introduction

• • Table 5-1: Europe Molecular Dx Market for Oncology – Histology, Assays, 2019-2025 ($ millions) (Molecular Histology; Molecular Assays, including CDx; Total. Molecular HPV)
• • Table 5-2: Europe (EU13, Eastern Europe, Russia, Switzerland) Molecular Dx Market for Oncology, 2020-2025 ($ millions)

Reimbursement Structure, Challenges and Recent Activity
EU15

• • Table 5-3: EU15 – Top 10 Cancer Incidences, 2018
• • Figure 5-1: EU15 – Leading Cancer Incidence Distribution, 2018 (%) (Breast, Lung, Prostate, Colorectum, Bladder, Non-Hodgkin lymphoma, Melanoma of skin, Pancreas, Kidney, Leukemia, Others)

Eastern Europe

• • Table 5-4: Eastern Europe – Top 10 Cancer Incidences, 2018
• • Figure 5-2: Eastern Europe – Leading Cancer Incidence Distribution, 2018 (%) (Breast, Lung, Prostate, Colorectum, Bladder, Corpus uteri, Kidney, Stomach, Pancreas, Melanoma of skin, Others)

Russia

• • Table 5-5: Russia – Top 10 Cancer Incidences, 2018
• • Figure 5-3: Russia – Leading Cancer Incidence Distribution, 2018 (%)

Switzerland

• • Table 5-6: Switzerland – Top 10 Cancer Incidences, 2018
• • Figure 5-4: Switzerland – Leading Cancer Incidence Distribution, 2018 (%) (Breast, Lung, Prostate, Colorectum, Melanoma of skin, Bladder, Non-Hodgkin lymphoma, Pancreas, Thyroid, Corpus uteri, Others)

Six: Cancer Molecular Diagnostics Markets, APAC
Introduction

• • Table 6-1: APAC Molecular Dx Market for Oncology – Histology, Assays, 2019-2025 ($ millions) (Molecular Histology; Molecular Assays, including CDx; Total. Molecular HPV)
• • Table 6-2: APAC (Japan, China) Molecular Dx Market for Oncology, 2020-2025 ($ millions)

Cancer Burden in APAC
Japan

• • Table 6-3: Japan – Top 10 Cancer Incidences, 2018
• • Figure 6-1: Japan – Leading Cancer Incidence Distribution, 2018 (%) (Colorectum, Lung, Stomach, Prostate, Breast, Pancreas, Bladder, Liver, Non-Hodgkin lymphoma, Gallbladder, Others)
• Reimbursement Environment in Japan

China

• • Table 6-4: China – Top 10 Cancer Incidences, 2018
• • Figure 6-2: China – Leading Cancer Incidence Distribution, 2018 (%) (Colorectum, Lung, Stomach, Liver, Breast, Oesophagus, Thyroid, Pancreas, Cervix uteri, Prostate, Others)
• • Table 6-5: Recent Partnerships Established between Illumina and Diagnostics Companies in China
• Reimbursement Environment in China

India

• • Table 6-6: India – Top 10 Cancer Incidences, 2018
• • Figure 6-3: India – Leading Cancer Incidence Distribution, 2018 (%) (Breast; Lip, oral cavity; Cervix uteri; Lung; Stomach; Colorectum; Oesophagus; Leukemia; Ovary; Larynx; Others)
• Reimbursement Environment in India
• ASEAN

Seven: Molecular Diagnostic Company Profiles
Abbott Diagnostics

• • Table 7-1: Abbott Diagnostics’ Recent Revenue History ($ millions)

Agendia BV
ARUP Laboratories

• • Table 7-2: ARUP Labs’ Recent Revenue History ($ millions)

Asuragen Inc.
Biocartis

• • Table 7-3: Biocartis’ Recent Revenue History ($ millions)

Biodesix
bioMÈrieux Inc.

• • Table 7-4: bioMÈrieux’s Recent Revenue History ($ millions)

BioReference Laboratories
Biotheranostics, Inc.
DiaSorin S.p.A

• • Table 7-5: DiaSorin’s Recent Revenue History ($ millions)

Enzo Biochem Inc.

• • Table 7-6: Enzo Biochem’s Recent Revenue History ($ millions)

Epigenomics AG
Exact Sciences Corp.

• • Table 7-7: Exact Sciences’ Recent Revenue History ($ millions)

Exosome Diagnostics, Inc.
Guardant Health, Inc.

• • Table 7-8: Guardant Health’s Recent Revenue History ($ millions)

Helomics Corporation
Hologic, Inc.

• • Table 7-9: Hologic’s Recent Revenue History ($ millions)

Illumina, Inc.

• • Table 7-10: Illumina’s Recent Revenue History ($ millions)

LabCorp, Laboratory Corporation of America

• • Table 7-11: LabCorp’s Recent Revenue History ($ millions)

Mayo Medical Laboratories
MDxHealth SA

• • Table 7-12: MDxHealth’s Recent Revenue History ($ millions)

Myriad Genetics, Inc.

• • Table 7-13: Myriad Genetics’ Recent Revenue History ($ millions)

NanoString Technologies, Inc.

• • Table 7-14: NanoString Technologies’ Recent Revenue History ($ millions)

NeoGenomics

• • Table 7-15: NeoGemonicsí Recent Revenue History ($ millions)

OPKO Health, Inc.

• • Table 7-16: OPKO Health’s Recent Revenue History ($ millions)

Pacific Biosciences of California, Inc. (PacBio)

• • Table 7-17: Pacific Biosciences of California’s Recent Revenue History ($ millions)

QIAGEN N.V.

• • Table 7-18: QIAGEN’s Recent Revenue History ($ millions)

Quest Diagnostics

• • Table 7-19: Quest Diagnostics’ Recent Revenue History ($ millions)

Roche Diagnostics

• • Table 7-20: Roche Diagnostics’ Recent Revenue History ($ millions)

Thermo Fisher Scientific Inc.

• • Table 7-21: Thermo Fisher’s Recent Revenue History ($ millions)

Trovagene, Inc.

• • Table 7-22: Trovagene’s Recent Revenue History ($ millions)

Veracyte, Inc.

• • Table 7-23: Veracyte’s Recent Revenue History ($ millions)